Nutritional Advice El Mondo
Objectives:
People who are exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could develop a potentially fatal disease with lung involvement and severe cytokine storm syndrome (CSS) - coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) was administered to these subjects, despite the lack of randomized clinical trial data. Hence, summarizing data on the mortality rate and related risks factors may help physicians to correctly administer tocilizumab. Therefore, this review article has been conducted.
Does tocilizumab reduce mortality risk in severe COVID-19 patients?
Study design:
This review article included 22 studies with a total of 1,520 tocilizumab-treated patients [mean age: 61 years, 95% CI = 59 to 64 and male: 71%, 95% CI = 64% to 78%].
Factors associated with the mortality are the number of patients in intensive care unit, the number of patients requiring invasive ventilation and the serum C-reactive protein value before tocilizumab administration.
Results and conclusions:
The investigators found that the mortality estimated pooled prevalence was 19% [95% CI = 13 to 25, I2 = 100%, p 0.00001] and improvement estimated pooled prevalence was 71% [95% CI = 62 to 81].
The investigators found a significantly lower mortality risk of 53% in tocilizumab-treated patients when compared to those treated with other therapies [OR = 0.47, 95% CI = 0.22 to 0.98, p = 0.004].
The investigators concluded that the mortality pooled prevalence in tocilizumab-treated patients is lower than the overall mortality reported in patients with severe COVID-19.
Original title:
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis by Berardicurti O, Ruscitti P, […], Giacomelli R.
Link:
https://pubmed.ncbi.nlm.nih.gov/33275094/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.